Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 39.56M P/E - EPS this Y - Ern Qtrly Grth -
Income -16.83M Forward P/E - EPS next Y - 50D Avg Chg 14.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -15.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -78.00%
Recommedations - Quick Ratio 0.19 Shares Outstanding 33.84M 52W Low Chg 68.00%
Insider Own 27.61% ROA -291.87% Shares Float 23.92M Beta -3.36
Inst Own 2.99% ROE - Shares Shorted/Prior 222.80K/65.93K Price 1.55
Gross Margin - Profit Margin - Avg. Volume 176,445 Target Price -
Oper. Margin - Earnings Date Oct 2 Volume 43,516 Change -4.32%
About OKYO Pharma Limited

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited News
11/15/24 MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
10/30/24 OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
10/23/24 OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
10/17/24 OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug
10/16/24 OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
09/10/24 OKYO Pharma Announces Chairman Acquires Shares
08/27/24 OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
08/23/24 OKYO Pharma CEO Interview to Air on Bloomberg TV
08/23/24 OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
08/15/24 OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
08/06/24 OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
07/11/24 OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
07/10/24 OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
05/08/24 OKYO Pharma Announces Participation in May 2024 Investor Conferences
04/30/24 OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
04/08/24 OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
04/02/24 OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
03/22/24 OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
06:00 AM OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
03/20/24 OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
OKYO Chatroom

User Image tkrvero Posted - 1 day ago

$OKYO just read Orphan drug approval straight thru FDA approval is ready. I hope is not just a troll as I buying 2000 shares

User Image tkrvero Posted - 1 day ago

$OKYO how can anyone not gamble on this company. Phase 2 has now been approved and for $1 I can give up a cartoon or two plus a few beers and buy a boat load of this. It’s not even a gamble as I see it. You can make a bundle here

User Image tkrvero Posted - 2 days ago

$OKYO ok took a shot in #APLD so thought ehy not take a look at OKYO and found they are going into a phase 2 research. Looks like if they make this a great period I may also dowrkk here. Just bought 2000 and will just sit on it as it for sure go up and down for a month or two but look out if they get approval for phase 3. You don't want to miss this chance

User Image Lurker_Investor Posted - 4 days ago

$OKYO https://www.youtube.com/watch?v=ZzLtKuPvFcM

User Image Schlaumi2 Posted - 5 days ago

$OKYO https://www.redchip.com/media/3142/inside-okyo-pharmas-nasdaq-okyo-phase-2-trials-with-ceo-dr-gary-jacob

User Image rp6577 Posted - 1 week ago

$OKYO 2025 is going to be huge for Okyo

User Image AnnKan Posted - 1 week ago

$CGBS this is a real LNG gem many will catch on soon the fundamental are too good ! $CVX $SHEL $OXY $OKYO TRUMP will soon remove all bans on LNG projects ! 💚

User Image gabbar111 Posted - 2 weeks ago

$EYEN $EYPT $KOD $OCUL $OKYO

User Image lucky9150 Posted - 2 weeks ago

$OKYO , $ 2 on Monday after Saturday's data presentation.

User Image SAUCEBOSS3000 Posted - 10/28/24

$OKYO finally waking up this bitch has been pinned at 1 for months but always held the line nicely

User Image SadyK189 Posted - 10/27/24

Top Stocks to watch next week 3 / 3: $PHUN Initially alerted at 4.30. Afterwards, it has made a nice run to $15. Currently at 10.66. Still looking good on daily chart. Key support at 8.35 - 8.75. It can test 11.8 - 12.65 zone again. $CAPR Initially alerted at 9.11. Kept posting about it regularly. Still trending strongly on weekly chart. Key support at 15.5 - 16.3. Next key level to test is 24 - 25.30. It may take sometime though. $OKYO looking good on 4hours chart. Key support at 0.97 - 1.03. Next key level to test is 1.68 - 1.85. It may take sometime though. $PCT Alerted for $11+ at 7.87. Still looking good on daily chart. Key support at 10.70 - 11.25 zone. Next key zone to test is 15.85 - 16.55. $HCTI Looking good on 4hours chart. Key support at 0.73 - 0.76. Currently at 0.90. Next key level to test is 1.25 - 1.45.

User Image rp6577 Posted - 10/25/24

$OKYO a lot of people wanting a piece of this sleeping giant ahead of some great data in early 2025. Orphan Drug Designation may also allow it to go straight to FDA approval $XBI

User Image auzzy Posted - 10/24/24

$OKYO Conference tomorrow

User Image LionEagle Posted - 10/24/24

$OKYO jumping in today. I agree with Jim Roppel that biotech is undervalued.

User Image rp6577 Posted - 10/23/24

$TLSA $OKYO moving well which is helping Tiziana given its investment in the company. If they get good NCP phase 2 data early next year, I wouldn’t be surprised if OKYO is sold, having two completed phase 2 trials for DED and NCP and orphan drug designation. It’s a sleeping giant. Huge cash injection for Tiziana at that point. This could also come at a time when Tiziana gets its own MS phase 2 data out. Early 2025 could be absolutely massive $XBI $LABU

User Image GmanPA Posted - 10/23/24

$OKYO Any gas left in the tank here? Love to trade. Just sold my PHUN. Of course it’ll go to $30 now. Whatever. Scooped 2500 TSLL at $10.77 after hours. Good report from Tesla.

User Image rp6577 Posted - 10/23/24

$OKYO ripping $XBI $DRUG

User Image rp6577 Posted - 10/23/24

$OKYO breaking higher $XBI $LABU

User Image prismmarketview Posted - 10/23/24

$OKYO https://prismmarketview.com/looking-good-okyo-pharma-doses-first-patient-in-phase-2-trial-for-corneal-neuropathic-pain-shares-rise-15/

User Image jParkz Posted - 10/23/24

$OKYO News out OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain https://marketwirenews.com/news-releases/okyo-pharma-announces-first-patient-dosed-in-the-fir-8076851205071699.html $OKYO

User Image sp500updown Posted - 10/22/24

$OKYO I just saw a commercial for this stock.... they have enough money to advertise? well whatever here's 1k ....not even gonna pretend to think I know how to evaluate a stock. YOLO. gotta spend these trading profits on something. People have eyes right? this company does eye stuff baby!

User Image yus37 Posted - 1 month ago

$EYEN I need to do some more DD on this name before deciding to add or sell.... Any bull or bear thesis is welcome! $EYPT $OCUL $KOD $OKYO

User Image prismmarketview Posted - 1 month ago

$OKYO https://prismmarketview.com/okyo-pharma-initiates-phase-2-trial-for-neuropathic-corneal-pain-treatment/

User Image rp6577 Posted - 1 month ago

$OKYO great news $XBI $LABU

User Image Zerocool3 Posted - 1 month ago

$OKYO What about phase 3? Doesn't it come after phase 2 and should start slowly according to Okyo's pipeline?

User Image rp6577 Posted - 1 month ago

$OKYO expecting a sizeable move soon $XBI

User Image rp6577 Posted - 1 month ago

$OKYO could get bought out at any moment

User Image rp6577 Posted - 09/24/24

Also potentially relevant for $TLSA and $OKYO $XBI going to be supportive going forward as well

User Image rp6577 Posted - 09/22/24

$OKYO Published 27th August 2024 - management expecting to begin phase 2 NCP trial in 3Q24. Therefore, should hear news this coming week. 7$ price target https://okyopharma.com/wp-content/uploads/2024/08/OKYO-Analyst-report-August-2024.pdf Also in the patent announcement in August the company stated: ‘The company continues to explore strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline candidates’ Could be a lot of good news on the way 🔥 Further supported by a general biotech rally and a rising $XBI

User Image rp6577 Posted - 2 months ago

$OKYO starting to creep back up

Analyst Ratings
HC Wainwright & Co. Buy Aug 27, 24
HC Wainwright & Co. Buy Jul 12, 24
HC Wainwright & Co. Buy Jul 11, 24
HC Wainwright & Co. Buy Mar 22, 24
HC Wainwright & Co. Buy Jan 8, 24
HC Wainwright & Co. Buy Dec 5, 23
HC Wainwright & Co. Buy Nov 2, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BRANCACCIO JOHN P Director Director Sep 15 Buy 1.50 16,670 25,005 16,670 09/28/23
CERRONE GABRIELE M Executive Chairman Executive Chairman May 19 Buy 0.076 5,800,000 440,800 548,981,215 05/20/22